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        Big Science and biomedical research 
  Big Science may be a controversial 
  issue among biomedical scientists to-
day, but the idea is not new. 40 years 
ago, nuclear physicist Alvin Weinberg 
coined the term Big Science to de-
scribe the large-scale approaches that 
were needed to develop modern nuclear 
technologies (  1  ). Weinberg foresaw a 
similar need in biomedical science, but 
cautioned that the success of such 
large-scale approaches would depend 
on their acceptance by biomedical sci-
entists and the government agencies 
that support them. Weinberg was cor-
rect in predicting the current resistance 
to Big Science, and he was not shy in 
condemning that resistance.   “  Biomed-
ical science is not done, or, more im-
portant, is not supported by the public 
simply because it gives intense satis-
faction to the dedicated and success-
ful biomedical  researcher.  ”   Weinberg 
stated,   “  It is supported on a really large 
scale because out of it have come means 
of eliminating man  ’  s infi  rmities.  ”   Al-
bert Sabin subscribed to a similar phi-
losophy, calling for a   “  concentrated 
attack on the more complex disease 
problems  ”   and the need to develop the 
necessary mechanisms to facilitate and 
coordinate collaborative research (  2  ). 
“Biomedical science…is supported on 
a really large scale because out of 
it have come means of eliminating 
man’s infirmities.” -Alvin Weinberg
  Neither Weinberg nor Sabin saw 
any contradiction between the Big Sci-
ence approach to biomedicine and the 
more traditional ways of doing science. 
Weinberg emphasized that nothing he 
had said to promote a collaborative ap-
proach to science implied that he con-
sidered individual research obsolete. In 
calling for more biomedical science, he 
  “  pleaded both for more Big Science 
and for more Little Science.  ”   Sabin also 
expressed his strong support for Little 
Science.   “  The importance of an indi-
vidual scientist  ’  s search for knowledge 
for its own sake as the very foundations 
of scientifi  c endeavor must continue to 
be supported and expanded if science is 
to provide the means for the solutions 
of the many problems of importance to 
human welfare.  ”   
  We fully agree with them. We 
strongly believe that the ability of sci-
ence to address and solve some of the 
major global health problems will re-
quire both the creativity of individual 
investigators and the infrastructure, sys-
tems, and resources needed to  effi   ciently 
harness scientifi  c knowledge to develop 
practical solutions. These two approaches 
to biomedical science are not in contra-
diction, but are complementary and mu-
tually stimulating. 
  The evolution of the biomedical 
research enterprise 
  With the increasing complexity of sci-
ence and the extraordinary diffi   culty 
of some of the problems we are tack-
ling, scientifi   c research is evolving 
into a highly elaborate enterprise with 
multiple partners that must work in 
a well-coordinated  fashion.  Physicist 
Albert-Laszlo Barab  á  si recently described 
how most great thinkers of the past 
published alone, yet built on each 
  other  ’  s work in an informal communica-
tions network of scholars that historian 
Derek De Solla Price called   “  the invis-
ible college.  ”   (  3, 4  ) In the 20th cen-
tury, science became an increasingly 
collaborative enterprise, but usually of 
small groups (e.g., Watson and Crick). 
The invisible college of the preceding 
century later began to take formal shape 
and became more organized, with in-
visible links being replaced by coau-
thorships of publications. More recent 
developments are leading to large col-
laborations, such as the Human Genome 
Project (HGP), the popular prototype 
of big biology. 
  When the HGP was proposed and 
launched some 20 years ago, it was re-
ceived with mixed feelings and many 
objections, caused especially by the 
fear that it would monopolize funds 
that would otherwise support investi-
gator-initiated research. The HGP was 
also perceived of as a project of limited 
scientifi  c value that was not driven by 
any specifi  c  hypothesis  (  5, 6  ). Other 
objections were more technical, in-
cluding the argument that the technol-
ogies necessary to sequence the human 
genome were not available (  7  ). How-
ever, when the working draft of the 
human genome was published in 2001, 
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  The Enterprise model represents a 
new way of thinking about problems, 
with the formulation of a shared scien-
tifi  c strategic plan. It represents a new 
way of solving problems, using common 
tools, optimized resources, and iterative 
learning. Most importantly, it represents 
a new way for scientists to behave as a 
global community of problem-solvers, 
sharing materials and information while 
recognizing the need to fi  nd the correct 
balance between collaboration and com-
petition, both of which are important 
driving forces of scientifi  c  discovery 
and innovation. 
  The Enterprise is being developed 
not as a new organization, but as an 
  alliance of independent organizations 
that are committed to accelerating the 
development of a preventive HIV vac-
cine by implementing a shared scientifi  c 
strategic plan, mobilizing additional 
  resources, and collaborating more in-
tensely among HIV vaccine researchers 
worldwide. The Enterprise Scientifi  c 
Strategic Plan makes broad suggestions 
in diff  erent areas in the HIV vaccine 
R  &  D continuum, providing a road map 
that funding and research agencies can 
use to plan or align at least some of their 
activities in a coordinated fashion (  13  ). 
  The fi  rst two initiatives launched in 
support of the Enterprise plan are the 
Center for HIV Vaccine Immunology 
(CHAVI), and the Collaboration for 
AIDS Vaccine Discovery (CAVD). 
CHAVI is a virtual center supported by 
the National Institute of Allergy and 
In  fectious Diseases (NIAID), which is 
composed of a large consortium of uni-
versities and academic medical centers 
working on new vaccine strategies to 
overcome key immunological road-
blocks in HIV vaccine design (  14  ). 
  The CAVD is being developed as a 
highly collaborative network of sixteen 
research consortia supported by the Bill 
  &   Melinda Gates Foundation (  15  ). 
Eleven of the consortia are working on 
diff  erent approaches to developing HIV 
vaccines, guided by the creativity of 
individual investigators. These vaccine 
discovery teams are supported by fi  ve 
central service facilities, which conduct 
immunological evaluations and data 
and statistical analysis for the whole 
was the further development of the 
fi   eld of retrovirology, which allowed 
for the rapid identifi  cation,  isolation, 
and study of HIV, the retrovirus that 
causes AIDS. 
  Other biomedical fi   elds are now 
stepping into big biology, and new ini-
tiatives are striving to integrate Little 
with Big Science (  11  ). One of these ini-
tiatives is the Global HIV Vaccine En-
terprise (the Enterprise). 
“The Enterprise…represents a new 
way for scientists to behave as a glo-
bal community of problem-solvers, 
sharing materials and information 
while recognizing the need to find 
the correct balance between collabo-
ration and competition.”
  The Global HIV Vaccine Enterprise 
  Soon after HIV was identifi   ed as the 
cause of AIDS in 1983  –  1984, there was 
an expectation that an eff  ective vaccine 
would be easily developed and rapidly 
deployed. The intense research eff  ort 
conducted during the last 20 years has 
produced important information on the 
virus and the disease, but a safe and ef-
fective vaccine remains elusive. To con-
front this challenge, in 2003 a group of 
leaders in the fi  eld of HIV vaccines pro-
posed the creation of the Global HIV 
Vaccine Enterprise (  12  ). They recog-
nized that current attempts to develop 
such a vaccine were insuffi   cient in scale 
and/or focus, and that a renewed HIV 
vaccine research eff  ort was required. 
  The Enterprise proposes to comple-
ment individual investigator-driven re-
search with a Big Science model to 
address this problem, taking full advan-
tage of new scientifi  c  opportunities, 
creating new strategies for collaborative 
partnerships, and organizing a more co-
ordinated global eff  ort. To achieve its 
goal, the Enterprise proposes to (a) pri-
oritize key scientifi  c questions and rap-
idly direct resources to try to answer 
the most critical questions; (b) support 
product development, manufacturing, and 
testing of novel candidate vaccines; and 
(c) implement common standards and pro-
cesses to maximize learning through the 
sharing of data and materials. 
it was considered the crown jewel of 
20th century biology, heralding the 
coming of age of Big Science in bio-
medicine (  5  ). 
  It can be argued that the eventual 
success of the HGP depended mostly 
on the development of technologies for 
DNA sequencing rather than on the 
  solution of fundamental scientifi  c ques-
tions. From that perspective, the HGP 
could be considered more of an engi-
neering project than a purely scientifi  c 
one, and thus it might not serve as a 
model for more scientifi  cally challenging 
areas of research. However, the many prob-
lems encountered in sequencing the hu-
man genome were not trivial, and the 
solutions were grounded in the best sci-
ence. Many lessons were also learned from 
the HGP that are relevant to other large-
scale biomedical projects (  8  ). 
  An earlier experiment on large-scale 
science was the   “  War on Cancer,  ”   offi   -
cially launched by President Nixon in 
1971 as the National Cancer Act. It 
aimed to support research and the ap-
plication of the results of research, to 
reduce the incidence, morbidity, and mor-
tality from cancer (  “  insofar as possible  ”  ). 
A major diff  erence between the War 
on Cancer and the HGP was the need 
to solve many fundamental scientifi  c 
questions in cell and cancer biology 
  before that knowledge could be used 
practically in prevention and treatment. 
Two of the arguments that were raised 
against the War on Cancer were that 
money couldn  ’  t buy ideas, and that 
  research was a process that was best 
left  unfocused. Nevertheless, the pro-
gram developed a research agenda that 
was broad enough to attract brilliant 
people who generated many new ideas 
but, at the same time, maintained the 
necessary focus on the applications of 
the results of research (  9, 10  ). Cancer 
may not be conquered yet, but the 
overall incidence, mortality, and mor-
bidity from cancer have decreased. Al-
though it is diffi   cult to attribute these 
gains directly to the War on Cancer, 
surely this program had a major impact 
on the outcome. In addition to the ex-
pected advances in cancer, the science 
derived from this program paid many 
other dividends. One such dividend JEM VOL. 204, April 16, 2007  703
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driven basic research and targeted re-
search. The fi  rst is driven by the search 
for basic knowledge, and the latter by 
the search for solutions. Again, we 
would like to argue that there is no real 
tension here. Both driving forces of sci-
ence are equally important and, indeed, 
they often synergize, as was convinc-
ingly argued by the late political scientist 
Donald Stokes in his book   “  Pasteur  ’  s 
Quadrant  ”   (  21  ). The basic science eff  ort 
needs to be protected at any cost, he ar-
gued, not only because of its intrinsic 
value but also because it is the engine 
that drives any future application. 
  Certainly another major source of 
tension is the competition for fi  nancial re-
sources between the larger, more expen-
sive collaborations, and the individually 
led eff  orts (  22  ). With a balanced funding 
approach such tensions can be mitigated. 
  Future directions 
  Four decades after Weinberg and Sabin 
challenged the biomedical community 
to take the bold step of thinking big, 
large-scale biomedicine is still strug-
gling to develop. Now is the time to 
understand the benefi  ts of the concept 
and embrace it. 
  However, even as the biomedical 
community moves in this direction it 
must recognize that innovation is the 
key to the success of both Little and Big 
Science (  23, 24  ). Some of the Enterprise 
partners are already discussing a new 
project to support novel high-risk/high-
reward ideas in HIV vaccine research, 
such as complementing the CAVD with 
an innovation component. Such pro-
grams are vital to maintaining an excit-
ing scientifi  c environment and attracting 
the new generations of scientists who are 
most likely to fi  nd the solutions to some 
of the intractable problems we are con-
fronting in biomedicine today (  25  ). To 
bring young scientists to the fi  eld, regard-
less of whether it is framed as Big or Little 
Science, we may need to address the so-
called   “  Matthew eff  ect,  ”   proposed by so-
ciologist Robert K. Merton, to describe 
the advantages that well-established sci-
entists have in gaining recognition, vis-
ibility, and research resources (  26  ). 
  When the ultimate result of a Big 
Science project, such as the Enterprise, 
when the HGP and the War on Cancer 
were fi  rst launched (  17, 18  ). 
  One confl  ict is between what some 
people call  “  individual thinking, ”   where 
science is based entirely on the creativ-
ity of individual investigators working 
more or less in isolation, and   “  group 
thinking,  ”   where scientifi  c exploration 
is guided by the collective wisdom of 
experts. We would like to argue that 
there is no real tension between these 
two approaches, and that the individual 
creativity of investigators can be aug-
mented by a more targeted and collab-
orative plan and vice versa (  19  ). The key 
to success is to be able to constantly ex-
plore new concepts and ideas, to make 
calculated risks, to make decisions based 
on evidence not on advocacy, and to en-
hance the individual research eff  ort with 
mechanisms that allow us to harness new 
knowledge to produce new solutions. 
  Although the creativity of individ-
ual investigators is often touted, it is also 
important to recognize that such cre-
ativity can, in practice, be limited by 
the   “  current scientifi  c  paradigm,  ”   a 
concept proposed by physicist Thomas 
Kuhn in 1962 (  20  ). He argued that the 
academic community is extremely ho-
mogeneous and conservative, which 
creates an environment that may not be 
entirely conducive to innovation. Pro-
moting truly innovative ideas can be 
very risky. If these ideas are funded 
(which is not often the case), they have 
a high possibility of failure. Thus, para-
doxically, the same scientifi  c community 
that places a high value on creativity and 
innovation has established peer-review 
mechanisms that maintain scientifi  c prog-
ress within the boundaries of the current 
paradigm. According to Kuhn, real scien-
tifi  c progress occurs when a new para-
digm emerges that is more satisfactory 
than the current paradigm and drives 
the work of the scientifi  c community. 
“When society is faced with diseases 
with consequences as dire as those 
associated with AIDS, we cannot 
afford to work selfishly in silos and 
for personal gain.”
  Another identifi   ed tension is one 
that could exist between investigator-
  network, allowing for real-time com-
parison of the results. The CAVD 
grants are not intended to focus on ba-
sic discovery research. Instead, they 
  target a perceived strategic gap in the 
HIV vaccine research and development 
continuum, which is the translational 
or maturation phase. This phase is 
aimed at harnessing the vast amount of 
knowledge derived from basic research 
to produce the proof-of-concept ex-
periments required to proceed with 
confi  dence to the product development 
phase. To ensure that the whole eff  ort 
is bigger than the sum of its parts, the 
sixteen CAVD consortia and centers 
are bound together by a communica-
tion and alliance management strat-
egy, and by legal agreements to share 
materials and data among the diff  erent 
CAVD laboratories and, with time, 
with the rest of the Enterprise partners 
and the scientifi  c community at large. 
“The ultimate success of the 
Enterprise will be judged on its real 
contribution to accelerating the 
development of an HIV vaccine.”
  In addition to CHAVI and the 
CAVD, other projects and initiatives 
are currently being aligned with the En-
terprise Scientifi   c Strategic Plan and 
philosophy, and will be launched in the 
near future. The ultimate success of the 
Enterprise will be judged on its real 
contribution to accelerating the devel-
opment of an HIV vaccine. In this re-
gard, it is important to recognize that 
the major challenges we confront in 
the development of an HIV vaccine 
are scientifi   c, and scientifi  c  problems 
need scientifi  c solutions (  16  ). Therefore, 
a successful Enterprise will need to bring 
together the Big Science of the proposed 
large collaborative networks and the Lit-
tle Science approaches needed to ex-
plore a range of highly innovative ideas. 
  Tensions between Big Science and 
Little Science 
  This Big Science approach to organiz-
ing HIV vaccine research has under-
standably created anxieties among some 
members of the scientifi  c community 
that are reminiscent of those raised 704 THE DISCOVERY VALUE OF   “  BIG SCIENCE  ”   | Esparza and Yamada
is a product such as a vaccine or a medi-
cine, a critical requirement for success is 
partnership with industry. Pharmaceu-
tical and biotech companies bring skill 
sets that are highly complementary to 
those found in academia such as auto-
mation technology, project manage-
ment, medicinal and process chemistry, 
and manufacturing science. They also 
bring innovative biomedical scientists 
who can contribute to the eff  ort. 
  When society is faced with diseases 
with consequences as dire as those asso-
ciated with AIDS, we cannot aff  ord to 
work selfi  shly in silos and for personal 
gain. There are too many people wait-
ing anxiously for the solutions that we 
must deliver. 
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